搜尋結果
2016年6月23日 · Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe.
2023 Profile of Sanofi's Vaccines Business Unit References World Health Organization (2019) Immunization Facts in Pictures. Accessed October 2022 MAT-GLB-2200131 v2 – 12/2022 Page updated December 2022 Continue to Your Health Follow us Back to ...
2023年7月24日 · Base de données publique des médicaments ANSM - Mis à jour le : 24/07/2023 Dénomination du médicament VAXIGRIPTETRA, suspension injectable en seringue préremplie Vaccin grippal quadrivalent (inactivé, à virion fragmenté)
Attachment 1: Product AusPAR - Vaxigrip Tetra - Inactivated quadrivalent influenza vaccine (split virion) - Sanofi-Aventis Australia Pty Ltd - PM-2018-00583-1-2 FINAL 19 December 2019. This Product information was approved at the time this AusPAR was published.
2023年2月27日 · 近日,赛诺菲中国宣布,四价流感病毒裂解疫苗—凡尔佳® (VaxigripTetra®)6~35月龄适应症于2023年2月21日获得国家药品监督管理局 (NMPA)上市许可批准 ...
Vaccines, Inactivated. vaxigrip. VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®). Areas covered: This literature review summarizes ….
Microsoft Word - 1.4.3 VaxigripTetra PI NH20-21_proposed_Aug2020. 1. NAME OF THE MEDICINAL PRODUCT. VaxigripTetra, suspension for injection in pre-filled syringe. Quadrivalentinfluenza vaccine (split virion, inactivated) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Influenza virus (inactivated, split) of the following strains*: